Medicines Articles
A clinical trial at the Universidad Autónoma de Madrid (UAM) suggests that early administration of intravenous immune globulin (IVIG) could decrease the occurrence of new infections in transplanted individuals who present with hypogammaglobulinemia.
The Food and Drug Administration has approved atezolizumab in combination with fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients 2 years of age and older with stage III mismatch repair deficient colon cancer
The U.S. Food and Drug Administration has approved KERENDIA (finerenone) for adults with chronic kidney disease associated with type 1 diabetes.
The U.S. Food and Drug Administration has approved Lisraya (brepocitinib) tablets to treat dermatomyositis in adults.
The U.S. Food and Drug Administration has approved Takeda’s Orzeyful (oveporexton) tablets to treat narcolepsy type 1 in adults.
Avlayah (tividenofusp alfa-eknm) has been FDA-approved to treat some individuals with Hunter Syndrome (Mucopolysaccharidosis type II or MPS II).
The U.S. Food and Drug Administration has approved veligrotug-vvze (Lumvoa; Viridian Therapeutics) to treat thyroid eye disease.
The U.S. Food and Drug Administration has approved KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration in adults across most solid tumor indications for KEYTRUDA (pembrolizumab).
The U.S. Food and Drug Administration has granted a designation as breakthrough therapy to Wayrilz (rilzabrutinib), a novel oral, reversible Bruton’s tyrosine kinase inhibitor, for the treatment of patients with warm autoimmune hemolytic anemia.